Perioperative Nivolumab Boosts EFS in Resectable Lung Cancer
(MedPage Today) -- Adding nivolumab (Opdivo) to neoadjuvant chemotherapy followed by adjuvant treatment with the PD-1 inhibitor alone significantly increased event-free survival (EFS) for patients with resectable non-small cell lung cancer (NSCLC... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - May 16, 2024 Category: Hematology Source Type: news

ARRS: More chemo response details needed in breast MRI reporting
Several neoadjuvant chemotherapy response characteristics are often left out of breast MRI reports, suggest findings presented May 7 at the American Roentgen Ray Society (ARRS) annual meeting. In a talk delivered at the conference, Sheida Ebrahimi, MD, from the University of California, San Diego presented her team’s study, which showed that little to no reports indicate the timing of chemotherapy, changes in background parenchymal enhancement (BPE), and the type of response in the findings section. “This single-institution, quality improvement project suggests that there is an opportunity to improve the reporting of...
Source: AuntMinnie.com Headlines - May 15, 2024 Category: Radiology Authors: Amerigo Allegretto Tags: MRI Womens Imaging Source Type: news

ISMRM: MRI useful in predicting tumor response in breast cancer patients
Integrating MR elastography (MRE) in a routine MRI scanner and combining it with dynamic contrast-enhanced MRI (DCE-MRI) could predict complete pathological response at the end of neoadjuvant chemotherapy in breast cancer patients, according to a presentation at the International Society for Magnetic Resonance in Medicine (ISMRM) annual meeting. Researchers led by Aish Sinha, MBBS, from King’s College London in England demonstrated how combining DCE-MRI with MRE achieved high sensitivity and specificity in predicting complete pathological response. “Quantifying biomechanics throughout chemotherapy via MRE in conjunct...
Source: AuntMinnie.com Headlines - May 9, 2024 Category: Radiology Authors: Amerigo Allegretto Tags: ISMRM 2024 Source Type: news

ISRMM: MRI useful in predicting tumor response in breast cancer patients
Integrating MR elastography (MRE) in a routine MRI scanner and combining it with dynamic contrast-enhanced MRI (DCE-MRI) could predict complete pathological response at the end of neoadjuvant chemotherapy in breast cancer patients, according to a presentation at the International Society for Magnetic Resonance in Medicine (ISMRM) annual meeting. Researchers led by Aish Sinha, MBBS, from King’s College London in England demonstrated how combining DCE-MRI with MRE achieved high sensitivity and specificity in predicting complete pathological response. “Quantifying biomechanics throughout chemotherapy via MRE in conjunct...
Source: AuntMinnie.com Headlines - May 9, 2024 Category: Radiology Authors: Amerigo Allegretto Tags: ISMRM 2024 Source Type: news

Neoadjuvant Chemohormonal Therapy Aids Locally Advanced Prostate Cancer
THURSDAY, May 2, 2024 -- For patients with locally advanced prostate cancer, neoadjuvant chemohormonal therapy (NCHT) is beneficial for biochemical progression-free survival (bPFS), according to a study published online May 1 in The Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 2, 2024 Category: Pharmaceuticals Source Type: news

Bilateral Wilms Tumors That Grow During Chemo Mostly Stromal-Predominant
WEDNESDAY, April 17, 2024 -- Bilateral Wilms tumors (BWTs) that increase in size during neoadjuvant chemotherapy, especially in younger patients, are most often stromal-predominant, according to a study published online March 27 in the Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 17, 2024 Category: Pharmaceuticals Source Type: news

Neoadjuvant Chemo-IO Promising in Borderline Resectable Pancreatic Cancer
(MedPage Today) -- SAN DIEGO -- A preoperative combination of chemotherapy and immunotherapy (IO) appeared safe and effective for borderline resectable pancreatic cancer in a small pilot study, a researcher reported here. In the phase I/II trial... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - April 11, 2024 Category: Gastroenterology Source Type: news

UltraCon: Harmonic motion imaging tracks breast tumor response to chemo
AUSTIN -- Harmonic motion imaging can track mechanical property changes of breast tumors in response to neoadjuvant chemotherapy, a study presented April 9 at UltraCon found. In his presentation, Yangpei Liu from Columbia University in New York City discussed findings from his team’s study, which showed that harmonic motion imaging could be a predictor of early treatment response. “Harmonic motion imaging-derives changes in tumor mechanical properties are more robust in early complete pathologic response prediction than tumor sizes,” Liu said.Yangpei Liu from Columbia University in Ney York City discussed findings ...
Source: AuntMinnie.com Headlines - April 10, 2024 Category: Radiology Authors: Amerigo Allegretto Tags: Ultrasound Womens Imaging Source Type: news

Does Neoadjuvant Chemoimmunotherapy Boost Survival in NSCLC? Does Neoadjuvant Chemoimmunotherapy Boost Survival in NSCLC?
A meta-analysis confirms that neoadjuvant chemoimmunotherapy improves survival outcomes in most patients with resectable NSCLC, except for overall survival in patients with baseline PD-L1 below 1%.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 25, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

QT Imaging to deliver Breast Acoustic CT scanner to research centers
QT Imaging Holdings is delivering its Breast Acoustic CT scanner in collaboration with research centers in the U.S. and Canada. The company is collaborating with the Department of Radiation Oncology and Radiation Treatment Program at the Sunnybrook Health Sciences Centre in Toronto, Ontario, Canada, and the University of Illinois, Urbana-Champaign. This collaboration is part of a five-year research grant from National Institutes of Health/National Cancer Institute to develop an inexpensive, portable, safe, and repeatable imaging approach that can accurately identify early response of breast cancer patients to neoadjuvant ...
Source: AuntMinnie.com Headlines - March 14, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news

Toward a Cure: Chemotherapy Plus TKI in EGFR-Mutant NSCLC Toward a Cure: Chemotherapy Plus TKI in EGFR-Mutant NSCLC
Dr Mark Kris discusses neoadjuvant approaches for patients non-small cell lung cancer with oncogenic drivers for which there are effective targeted therapies.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 13, 2024 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Neoadjuvant Chemo Adds Significant Treatment Benefit in Penile Cancer
THURSDAY, March 7, 2024 -- Neoadjuvant chemotherapy (NAC) with lymphadenectomy for locally advanced penile squamous cell carcinoma (PSCC) is well tolerated and improves outcomes, according to a study published online Feb. 16 in the Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 7, 2024 Category: Pharmaceuticals Source Type: news

In TNBC, Pathologic Complete Response May Vary by Race/Ethnicity
(MedPage Today) -- Among patients with triple-negative breast cancer (TNBC) who received neoadjuvant chemotherapy, the odds of achieving pathologic complete response (pCR) and improved overall survival (OS) may vary by race/ethnicity, according... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - February 28, 2024 Category: American Health Source Type: news

Tislelizumab Plus Chemotherapy Beneficial for Resectable NSCLC
FRIDAY, Feb. 23, 2024 -- For patients with resectable non-small cell lung cancer (NSCLC), neoadjuvant tislelizumab (TIS) plus chemotherapy with adjuvant TIS yields significant benefit in terms of event-free survival (EFS), according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 23, 2024 Category: Pharmaceuticals Source Type: news

Perioperative Tislelizumab Demonstrates Survival Benefit in NSCLC
(MedPage Today) -- Adding tislelizumab to neoadjuvant chemotherapy followed by adjuvant use of the investigational PD-1 inhibitor improved event-free survival (EFS) in resectable non-small cell lung cancer (NSCLC), a phase III trial from China... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 16, 2024 Category: Hematology Source Type: news